The GNMX ETF is an actively managed ETF that invests in companies involved in the precision medicine value chain, including genomic analysis, precision diagnostics, targeted therapies, and the use of clinical data. Rather than mechanically tracking a specific index, it selects securities based on the manager's judgment.

It suits long-term investors who are interested in the growth potential of the genomics and precision medicine industries and can tolerate clinical, regulatory, and commercialization risks.

The ETF is managed by Corgi Funds using an active management approach.

The fund selects companies with business ties to precision medicine as a whole, including genomic analysis, molecular diagnostics, gene editing, targeted therapies, and clinical data. It can reflect changes in R&D results and commercialization conditions more readily than index inclusion rules would allow, but the influence of the manager's judgment also grows.

• Active selection spanning the precision medicine value chain
• Reflects industry shifts and individual company conditions instead of tracking an index

Assets under management (AUM) stand at $1.3M, and the total expense ratio is 0.35% per year.

As a micro-cap ETF, its trading volume and bid-ask spreads can vary with market conditions. Investors should check order types and execution conditions, and compare the fee qualitatively with similar products in the same theme.

With a short track record, it is difficult to draw firm conclusions about long-term performance, and returns may be sensitive to clinical trial results, regulatory decisions, treatment accessibility, and shifting R&D expectations. It is advisable not to judge the durability of the theme from short-term moves alone.

For micro-cap ETFs, fund flows and trading participation can swing widely depending on market conditions. The precision medicine theme can be affected by investor sentiment, healthcare policy, reimbursement systems, and the progress of individual pipelines.

Its active structure focused on the precision medicine theme is a strength, while its micro-cap size and the industry's inherent uncertainty are factors to watch.

Comparable listed fund data is limited, and the candidate list provided was also empty, so we do not directly suggest individual alternative products. When reviewing the same theme, it is reasonable to check together whether a fund is actively managed, the scope of its exposure to genomic analysis and therapy development, its cost burden, trading liquidity, and distribution policy.

Before investing, consider whether the thematic exposure fits your personal asset allocation, whether you can accept the trading conditions of a micro-cap ETF, and whether the lack of distribution history is consistent with your cash flow goals. Scientific progress and investment performance do not always move in the same direction.

Because this ETF combines thematic concentration, active management, and micro-cap size, its risk profile differs from that of broad index ETFs. Scientific achievements may not translate directly into commercial success, and changes in regulation, reimbursement policy, and competing technologies can amplify volatility.

It may suit those seeking exposure to structural change in genomic analysis and precision medicine, but investors should account for the lack of distribution history, the characteristics of micro-cap ETFs, and industry-specific uncertainty. After checking the weight of the individual theme, long-term holding costs, and trading conditions, it is advisable to decide carefully within your overall asset allocation.